BRAF and non-small cell lung carcinoma: Finally, we explored the prognostic impact of BRAF non-V600 mutations on the outcomes of patients enrolled into two randomized controlled trials, the phase II POPLAR trial and the phase III OAK trial (POPLAR/OAK cohort), which demonstrated the superiority of atezolizumab 1200 mg over standard chemotherapy with docetaxel 75 mg/m2 in previously treated, squamous or non-squamous, advanced NSCLC patients [13,14,15].